ライフサイエンスコーパス: breast adenocarcinoma

1 an ovarian teratocarcinoma) and MCF-7 (human breast adenocarcinoma).

2 ally detected in women with gynecological or breast adenocarcinoma.

3 haryngeal squamous cell carcinomas, and in 1 breast adenocarcinoma.

4 e included lung adenomas, lymphomas, and one breast adenocarcinoma.

5 re tested for cytotoxicity in the MDA MB-361 breast adenocarcinoma.

6 and RANKL expression patterns seen in human breast adenocarcinomas.

7 ell lines, specially glioma, and ovarian and breast adenocarcinomas.

8 igen uMUC-1, which is found in >90% of human breast adenocarcinomas.

9 icant levels in human primary and metastatic breast adenocarcinomas.

10 Additional whole sections representing 10 breast adenocarcinomas, 10 normal breast tissues, and 16

11 ll populations in the immune response to rat breast adenocarcinoma 13762 was studied by selective dep

12 atumoral endothelial cells in 73% to 100% of breast adenocarcinomas, 18% of in situ ductal carcinomas

13 ly increased the apoptosis/necrosis ratio in breast adenocarcinoma and cervix carcinoma cells.

14 e a novel cDNA isolated from a primary human breast adenocarcinoma and differentially expressed in se

15 rmal growth factor (EGF) stimulation of T47D breast adenocarcinoma and embryonic kidney epithelial (H

16 pha and ERbeta and is an antagonist in MCF-7 breast adenocarcinoma and Ishikawa uterine cancer cell l

17 ptides from class I molecules of HLA-A2.1(+) breast adenocarcinoma and loaded reverse phase high-perf

18 nation of a set of human infiltrating ductal breast adenocarcinoma and lymph node metastasis tissues

19 verexpressing cancers such as pancreatic and breast adenocarcinoma and might contribute to the unders

20 wild types of human cancer cell lines, MCF-7 breast adenocarcinoma and SKOV-3 ovarian carcinoma, whil

21 We examined 296 breast adenocarcinomas and 38 ductal carcinoma in situ t

22 cal adenocarcinoma, T98G glioblastoma, MCF-7 breast adenocarcinoma, and HL-60 leukemia cells.

23 HER2-positive (HER2(+)) breast adenocarcinomas are a heterogeneous group in whic

24 of the same treatments in a rodent model of breast adenocarcinoma brain metastases.

25 ion in human U87 glioblastoma and MDA-MB-231 breast adenocarcinoma cancer cell lines.

26 s also tested on a clinically relevant human breast adenocarcinoma cell line (MCF-7/FLV1), exploits t

27 ayed antagonist behaviors in the MCF-7 human breast adenocarcinoma cell line as well in Ishikawa cell

28 ctive in inhibiting the proliferation of the breast adenocarcinoma cell line MCF-7 (IC50, 2 microM),

29 rachlorodibenzo-p-dioxin (TCDD) in the human breast adenocarcinoma cell line MCF-7 but not in the hum

30 heterogeneity in a single batch of the human breast adenocarcinoma cell line MCF-7 obtained directly

31 nique, we further performed CETCh-seq in the breast adenocarcinoma cell line MCF7 as well as mouse em

32 scriptomic and proteomic response of a human breast adenocarcinoma cell line to a chemical perturbati

33 s toward MCF-7 cells (human pleural effusion breast adenocarcinoma cell line).

34 rotein levels of Glut-1 and HKII in MCF-7, a breast adenocarcinoma cell line, and (3)H-FDG uptake, bo

35 growth inhibition effect was obtained in the breast adenocarcinoma cell line, reaching EC50 values of

36 In breast adenocarcinoma cell lines expressing multiple EPH

37 ermore, ectopic stable IL-6 expressing MCF-7 breast adenocarcinoma cells (MCF-7(IL-6)) exhibited an E

38 Using an isogenic model of MCF-7 breast adenocarcinoma cells (MCF-7E and MCF-7L sublines

39 They have lower toxicity to human breast adenocarcinoma cells (MDA-MB-468) and, most remar

40 We have reintroduced MTAP into MCF-7 breast adenocarcinoma cells and have examined its effect

41 We demonstrate that stimulation of 4T1 breast adenocarcinoma cells and K562 erythroleukemic cel

42 vered that ephrinA1 is released from GBM and breast adenocarcinoma cells as a soluble, monomeric prot

43 ing of implanted EMT6 murine and BT474 human breast adenocarcinoma cells by (18)F-FPIA PET showed rap

44 sic fibroblast growth factor is mitogenic to breast adenocarcinoma cells cultured in the conditioned

45 After single-step selection of breast adenocarcinoma cells in paclitaxel, differential

46 f full-length DEFCAP-L, but not DEFCAP-S, in breast adenocarcinoma cells MCF7 resulted in significant

47 Nanodrug uptake by human breast adenocarcinoma cells resulted in a significant do

48 Expression of MTAP in MTAP-deleted MCF-7 breast adenocarcinoma cells results in a significant red

49 human pancreatic (AsPC-1), colon (HT29), and breast adenocarcinoma cells T47D and MDA-MB-468 with the

50 of the EGF to target the GemC18-NPs to human breast adenocarcinoma cells that expressed different lev

51 Expression of activated Akt in MCF-7 breast adenocarcinoma cells was sufficient to block Fas-

52 values on colon carcinoma, glioblastoma, and breast adenocarcinoma cells were 8.51, 13.35, and 14.81

53 n monocyte), and MCF-7 and MDA-MB-231 (human breast adenocarcinoma cells) cell lines.

54 ate receptor and EpCAM on lung carcinoma and breast adenocarcinoma cells, respectively.

55 nge with T9 cells, but not syngeneic MadB106 breast adenocarcinoma cells, suggesting that T9-specific

56 ke of (18)F-FPIA was measured in murine EMT6 breast adenocarcinoma cells.

57 at high resolution in genomic DNA from human breast adenocarcinoma cells.

58 monary micrometastates in mice injected with breast adenocarcinoma cells.

59 Breast adenocarcinomas expressing high levels of ROR1 we

60 higher rates of relapse and metastasis than breast adenocarcinomas expressing low levels of ROR1.

61 sing erbB2, although erbB2-negative invasive breast adenocarcinomas frequently lacked expression of p

62 revealed that lead compound inhibited human breast adenocarcinoma growth in mice model.

63 ere challenged with cells from the unrelated breast adenocarcinoma line E0771 or the melanoma line B1

64 se transcription-PCR for expression in human breast adenocarcinoma lines (BrCa) and in normal nodes f

65 employed for the detection of miR21 in human breast adenocarcinoma MCF-7 cells and nontumorigenic epi

66 LDL-mediated proliferative response in human breast adenocarcinoma MCF-7 cells.

67 ll-binding studies were performed with human breast adenocarcinoma MCF-7 cells.

68 s optimum antiproliferative activity against breast adenocarcinoma (MCF 7 and MDA-MB-231) cells and t

69 nt cell lines (renal adenocarcinoma (TK-10), breast adenocarcinoma (MCF-7) and melanoma (UACC-62)) by

70 ma (HCT-8), human kidney carcinoma (CAKI-1), breast adenocarcinoma (MCF-7), and human malignant melan

71 our different human cancer cell lines [human breast adenocarcinoma (MCF-7), colorectal adenocarcinoma

72 Human breast adenocarcinoma MCF7 cells stably transfected with

73 prominent activity of water extracts towards breast adenocarcinoma (MCF7).

74 onse of live breast cancer MCF-7 and mammary breast adenocarcinoma MDA-MB 231 cell lines to severe he

75 that knockdown of WAVE3 expression in human breast adenocarcinoma MDA-MB-231 cells using small inter

76 ), colon adenocarcinoma (HT-29, 60-77%), and breast adenocarcinoma (MDA-MB-361, 66-71%) cells at a co

77 In a mouse breast adenocarcinoma model, fluorescently labeled pHLIP

78 various malignancies, including ovarian and breast adenocarcinomas, non-small-cell lung cancer, leuk

79 Breast adenocarcinomas (ranging from well to poorly diff

80 fied to secrete IL-2 with genomic DNA from a breast adenocarcinoma that arose spontaneously in a C3H/

81 h levels of RANK were found in human primary breast adenocarcinomas that lack expression of the hormo

82 er in invasive breast cancer tissues than in breast adenocarcinoma tissue.

83 ats (150 gm, n = 96) with subcutaneous R3230 breast adenocarcinoma tumors had normal non-tumor-bearin

84 eting efficiency and specificity of 2 to the breast adenocarcinoma tumors in mouse xenografts were fu

85 ER-negative MDA-MB-231 cells derived from a breast adenocarcinoma, we found that E2-ERalpha(EBD) mod

86 MCF-7 cells, a human breast adenocarcinoma, were retained on the array surfac